$ANGO News

AngioDynamics: NanoKnife Momentum Looks Real, But Much Of The Good News Is Priced In

HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $19

Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20

AngioDynamics (NASDAQ:ANGO) Surges on Strong Quarterly Beat as Med Tech Segment Drives Growth

AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript

Full Transcript: AngioDynamics Q4 2026 Earnings Call

AngioDynamics, Inc. 2026 Q4 - Results - Earnings Call Presentation

AngioDynamics Sees FY2027 Adj EPS $(0.29)-$(0.24) vs $(0.16) Est; Sees Sales $336.000M-$341.000M vs $329.600M Est

AngioDynamics Q4 Adj. EPS $(0.07) Beats $(0.09) Estimate, Sales $86.607M Beat $80.400M Estimate

AngioDynamics Says FDA Approves IDE Application To Initiate RELIEF Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment Option For Men With Benign Prostatic Hyperplasia

AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Slideshow

AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

Wall Street Analysts See a 50.5% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

AngioDynamics Announces 2-Yr Results From PRESERVE Pivotal Trial Demonstrating Durable Oncologic Control And Sustained Safety Profile For NanoKnife System In Focal Ablation Of Intermediate-Risk Prostate Cancer

Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet

AngioDynamics Files Patent Infringement Lawsuit Against Endovascular Engineering On April 23, 2026; Seeks Damages And Equitable Relief In Lawsuit Against Endovascular Engineering

Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade

AngioDynamics CEO Touts Debt-Free Turnaround, Auryon Share Gains, NanoKnife Launch at Needham Conf